Business Today

Vaccinating Indians above 18 years to cost less than 1% of annual GDP: India Ratings

A study by India Ratings and Research (Ind-Ra) has pegged the overall cost of vaccinating all Indians above 18 years of age against COVID-19 at Rs 67,193 crore, of which states together will incur Rs 46,323 crore

twitter-logoBusinessToday.In | April 23, 2021 | Updated 17:32 IST
Vaccinating Indians above 18 years to cost less than 1% of annual GDP: India Ratings
All Indian citizens aged 18 years and above will be eligible for vaccination against Covid-19 from May 1. (Photo: Reuters)

The cost of vaccinating all Indians above the age of 18 years against COVID-19 will be just 0.36% of India's annual GDP (Gross Domestic Product), according to a study by India Ratings and Research (Ind-Ra).

It pegged the overall cost at Rs 67,193 crore, of which states will incur Rs 46,323 crore.

The evaluation has been released at a time when the Centre and states are engaged in a debate over the pricing difference of coronavirus vaccines.

As the COVID-19 second wave sweeps the country with alarming pace and intensity, the Centre has announced a liberalised and expedited phase-3 strategy of COVID-19 vaccination.  Under this phase, all persons above 18 years of age will be eligible to get COVID-19 vaccine doses from May 1.

Also Read: COVID-19 vaccination: India needs 8 yrs 9 months to achieve herd immunity

This means that the total size of the population that will now be eligible for vaccination will be 84.19 crore out of a total population of 133.26 crore, Ind-Ra said in its report.

It calculated that this "may cost Rs 67,193 crore, of which the Union government will incur Rs 20,870 crore and state governments together will incur Rs 46,323 crore".

The government has made pricing, procurement, eligibility and administration of coronavirus vaccines flexible. While the Centre's vaccination drive will continue as before, providing free vaccination to priority populations such as healthcare workers, frontline workers and population above 45 years of age, states and union territories have been allowed to procure additional COVID-19 vaccine doses directly from the manufacturers and open up vaccination to people above the age of 18 years.

As a result, Indian vaccine manufacturers would now be supplying 50 per cent of their production to the central government and the balance 50 per cent would be available for procurement by the state governments and the open market (private hospitals).

Ind-Ra said the Centre has already spent Rs 5,090 crore on procuring 21.4 crore vaccines from Serum Institute of India and Bharat Biotech.

Also Read: India to expand COVID-19 vaccination but supplies run short, imports delayed 

Assuming two doses of vaccines at Rs 400 per dose for new procurement and 5 per cent wastage, the cost for the central government will come to Rs 62,103 crore for 155.4 crore doses, it said.

The total for the two comes to Rs 67,193 crore, which "works out to be just 0.36 per cent of GDP," it noted. "If we split it between the Union government and state governments, then the fiscal impact on the union budget would be 0.12 per cent of GDP and on state budgets would be 0.24 per cent of GDP".

The maximum impact is likely to be on Bihar (0.60 per cent of gross state domestic product or GSDP), followed by Uttar Pradesh (0.47 per cent), Jharkhand (0.37 per cent), Manipur (0.36 per cent), Assam (0.35 per cent), Madhya Pradesh (0.30 per cent) and Odisha (0.30 per cent).

"Since the antibodies generated by these vaccines are likely to last for 12-18 months, this expenditure would be a recurring expenditure on union and state budgets," it said.

Also Read: COVID-19 vaccine makers draw up plans to boost manufacturing after meeting with PM Modi

"However, many states such as Kerala, Chhattisgarh, Bihar and Madhya Pradesh have already announced that the government will bear the cost of vaccination. Vaccinations by large corporate groups will reduce pressure on the state/central budget," the study noted.

Ind-Ra believes that given the magnitude of the problem and the economic cost which the second wave of COVID-19 pandemic is likely to inflict on the economy, this is too small an amount.

"However, more than the money spent, the critical factor would be how soon the desired level of vaccination can be achieved.

"Therefore, the decision to allow the restricted emergency use of Russian vaccine Sputnik-V and other vaccines approved by the US, EU and WHO is another step in the right direction. This will only accelerate the vaccination effort in the country. The first batch of Sputnik V is expected to be delivered to India by April-end," the study added.

(With inputs from PTI.)

  • Print
A    A   A